Loading quotes...

Forecast

Buy	5
Hold	2
Sell	0

News Go to news feed

Celyad Oncology receives €500,000 from Fortress in private placement

Celyad Oncology has agreed a private placement with a subsidiary of Fortress Investment Group for €500,000 in exchange for 2.5 million new common shares at €0.20 each (15% discount). Closing is expected around July 15; after the issue Fortress would hold roughly 60.52% of the shares and about 68.75% of the voting rights. Net proceeds will be used for working capital and are intended to extend the company’s cash runway from Q3 2026 to mid‑Q2 2027; a committee of independent directors judged the transaction to be in the company’s interest. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Celyad Oncology has already paid €0.26 in dividends. The last payout was in March 2022.

Financials

In the last quarter, Celyad Oncology had revenue of €0 and net profit of -€1.21m

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	-43k	-
Net profit	-1.21m	-
EBITDA	-1.29m	-

Fundamentals

Metric	Value
Market capitalization	€9.92m
Number of shares	47.26m
52-week high/low	€0.65 - €0.16
Dividends	No
Beta	1.25
P/E ratio	2.53
PEG ratio	0.00
P/B ratio	7.48
P/S ratio	1,417.86

Company profile

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.